La vendita allo scoperto per ADMA Biologics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di ADMA Biologics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

ADMA Biologics (NASDAQ:ADMA) Azioni, Report sulle vendite allo scoperto

ADMA BIOLOGICS INC

ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

News

Markets

Media

Trading Ideas

ADMA

KEYS

NVCR

Il noto opinionista finanziario rivede la sua posizione su un&#39;azienda specifica, mentre altre vengono esaminate con cautela.

Jim Cramer ha cambiato idea? Ecco un titolo &#34;di nicchia&#34; che ora adora

ADMA Biologics Inc

Raymond James analyst Elliot Wilbur maintains ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Strong Buy and raises the price target from $25 to $32.

Price Target

Analyst Ratings

Raymond James Maintains Strong Buy on ADMA Biologics, Raises Price Target to $32

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 300 points on Thursday.
The Dow traded up 1.50% to 41,729.20 while the NASDAQ gained 1.91% to 18,076.43. The S&amp;P 500 also rose, gaining, 1.44% to 5,712.61.
Check This Out: <a href="https://www.benzinga.com/25/05/45283111/uber-to-rally-around-20-here-are-10-top-analyst-forecasts-for-thursday">Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday</a>
Leading and Lagging Sectors Energy shares rose by 1.2% on Thursday.
In trading on Thursday, health care stocks fell by 0.9%.
Top Headline
US Foods Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) reported weaker-than-expected earnings for the first quarter on Thursday.
The company posted quarterly earnings of 68 cents per share which missed the analyst consensus estimate of 69 cents per share. The company reported quarterly sales of $9.35 billion which missed the analyst consensus estimate of $9.38 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SunOpta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKL#NASDAQ">STKL</a>) shares shot up 30% to $5.91 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance above estimates. Additionally, the company announced a $25 million share repurchase program.</li>
<li>Shares of Sezzle Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) got a boost, surging 44% to $76.07 after the company reported better-than-expected first-quarter financial results and raised its FY25 guidance.</li>
<li>Solidion Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares were also up, gaining 37% to $0.13 after the company presented its patented technology for transforming lithium-ion facilities into battery producers.</li>
</ul>
Equities Trading DOWN
<ul>
<li>argenx SE &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) shares dropped 15% to $531.86 &nbsp;following first-quarter results.</li>
<li>Shares of Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) were down 68% to $0.1725 after the company announced exploration of strategic alternatives to maximize shareholder value.</li>
<li>ADMA Biologics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) was down, falling 19% to $19.09 following downbeat quarterly results.</li>
</ul>
Commodities In commodity news, oil traded up 2.4% to $59.48 while gold traded down 1% at $3,357.70.
Silver traded up 0.1% to $32.825 on Thursday, while copper fell 0.5% to $4.6385.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.37%, while Spain's IBEX 35 Index fell 0.13%. London's FTSE 100 slipped 0.30%, Germany's DAX 40 rose 0.77% and France's CAC 40 gained 0.84% during the session.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei gaining 0.41%, Hong Kong's Hang Seng Index gaining 0.37%, China's Shanghai Composite Index rising 0.28% and India's BSE Sensex falling 0.51%.
Economics
<ul>
<li>U.S. initial jobless claims declined by 13,000 to 228,000 in the week ending May 3, compared to market estimates of 230,000.</li>
<li>U.S. labor productivity in the nonfarm business sector declined by 0.8% during the first quarter compared to estimates of a 0.7% drop.</li>
<li>U.S. unit labor costs increased by 5.7% in the first quarter of compared to market estimates of a 5.1% gain. </li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/news/earnings/25/05/45284390/how-to-earn-500-a-month-from-mckesson-stock-ahead-of-q4-earnings">How To Earn $500 A Month From McKesson Stock Ahead Of Q4 Earnings</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Intraday Update

ARGX

SEZL

STKL

USFD

Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings

WIIM

ADMA Biologics shares are trading lower after the company reported worse-than-expected Q1 financial results.

ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) FY2026 Revenue expected to be more than $625.00M vs $629.23M Est

Guidance

ADMA Biologics FY2026  Revenue expected to be more than $625.00M vs $629.23M Est

ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) FY2025 Revenue expected to be more than $500.00M vs $495.10M Est

ADMA Biologics FY2025  Revenue expected to be more than $500.00M vs $495.10M Est

ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.16 by 12.5 percent. This is a 75 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $114.80 million which missed the analyst consensus estimate of $116.40 million by 1.37 percent. This is a 40.22 percent increase over sales of $81.88 million the same period last year.

Earnings Misses

ADMA Biologics Q1 Adj. EPS $0.14 Misses $0.16 Estimate, Sales $114.80M Miss $116.40M Estimate

ACAD

ACDC

ACRE

ACVA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate ADMA Biologics to report an earnings per share (EPS) of $0.14.
The announcement from ADMA Biologics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
The company's EPS missed by $0.01 in the last quarter, leading to a 7.45% increase in the share price on the following day.
Here's a look at ADMA Biologics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.15</td>
<td>0.13</td>
<td>0.08</td>
<td>0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.14</td>
<td>0.15</td>
<td>0.13</td>
<td>0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>15.0%</td>
<td>31.0%</td>
<td>27.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746543677_0.png" alt="eps graph" />
<h3>Tracking ADMA Biologics's Stock Performance</h3>
Shares of ADMA Biologics were trading at $23.71 as of May 05. Over the last 52-week period, shares are up 240.75%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Opinions on ADMA Biologics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on ADMA Biologics.
The consensus rating for ADMA Biologics is Outperform, based on 1 analyst ratings. With an average one-year price target of $25.0, there's a potential 5.44% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Ionis Pharmaceuticals, TG Therapeutics and Alkermes, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Ionis Pharmaceuticals, with an average 1-year price target of $54.15, suggesting a potential 128.38% upside.</li>
<li>Analysts currently favor an Buy trajectory for TG Therapeutics, with an average 1-year price target of $55.0, suggesting a potential 131.97% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Alkermes, with an average 1-year price target of $40.5, suggesting a potential 70.81% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary outlines pivotal metrics for Ionis Pharmaceuticals, TG Therapeutics and Alkermes, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA Biologics</td>
<td>Outperform</td>
<td>59.06%</td>
<td>$63.33M</td>
<td>38.52%</td>
</tr>
<tr>
<td>Ionis Pharmaceuticals</td>
<td>Buy</td>
<td>10.14%</td>
<td>$130.11M</td>
<td>-27.62%</td>
</tr>
<tr>
<td>TG Therapeutics</td>
<td>Buy</td>
<td>146.04%</td>
<td>$92.79M</td>
<td>11.26%</td>
</tr>
<tr>
<td>Alkermes</td>
<td>Neutral</td>
<td>-12.52%</td>
<td>$257.31M</td>
<td>1.51%</td>
</tr>
</tbody>
</table>

Key Takeaway:
ADMA Biologics ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity. Overall, ADMA Biologics is positioned favorably compared to its peers in terms of Revenue Growth and Gross Profit, but lags behind in Return on Equity.
<h3>Delving into ADMA Biologics's Background</h3>
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
<h3>ADMA Biologics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, ADMA Biologics showcased positive performance, achieving a revenue growth rate of 59.06% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 95.19%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 38.52%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): ADMA Biologics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 25.45% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: ADMA Biologics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.24.
<a href="https://www.benzinga.com/quote/ADMA/earnings">To track all earnings releases for ADMA Biologics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADMA Biologics Earnings Preview

ADMA Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) shares are trading higher Monday following the Food and Drug Administration&#8216;s (FDA) approval of its <a href="https://www.benzinga.com//node/45034986">yield enhancement process.</a>
What To Know: ADMA's yield enhancement process has demonstrated the ability to increase production yields by approximately 20% from the same starting plasma volume.
&#8220;This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond,&#8221; said Adam Grossman, President and CEO of ADMA.
Grossman added that the company is focused on advancing its internal Research and Development platform to further optimize production capabilities and develop new pipeline programs, most notably SG-001, an early-stage antibody therapy targeting S. pneumoniae.
What Else: The company is expected to report first-quarter earnings on May 12th. Analysts&#8217; estimate earnings per share of 16 cents and revenue of $116.40 million.
Related Link: <a href="https://www.benzinga.com/news/25/04/45046313/nuvve-expands-beyond-evs-with-bold-bitcoin-crypto-investment-arm">Nuvve Expands Beyond EVs With Bold Bitcoin, Crypto Investment Arm</a>
ADMA Price Action: At the time of publication, ADMA share are trading 9.79% higher at $24.00, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

Movers

What's Going On With ADMA Stock Monday?

ADMA Biologics shares are trading higher after the company announced FDA approval of its yield enhancement production process.

U.S. stocks were mostly higher, with the Dow Jones index gaining around 200 points on Monday.
Shares of CEMEX, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) rose sharply during Monday's session following <a href="https://www.benzinga.com/25/04/45038161/cemexs-q1-results-show-strong-emea-growth-offset-by-mexican-market-struggles">first-quarter results</a>.
The company reported first-quarter net sales of $3.65 million, missing the consensus of $3.80 billion. Net sales fell 7% year over year (Y/Y), mainly due to lower volumes in Mexico. EBITDA declined 18% Y/Y to $601 million in the quarter, with a margin contracted 2.0ppt Y/Y to 16.5% in the quarter.
Cemex expects recurrent yearly EBITDA savings of at least $150 million in 2025 and $350 million by 2027.
Cemex shares jumped 4.2% to $6.16 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares jumped 39.4% to $1.13 after the company signed a secured credit facility with Yorkville Advisors. The company also reported preliminary first-quarter results.</li>
<li>CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) surged 30% to $29.02 after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 24.5% to $4.07.</li>
<li>Sabre Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) gained 20.3% to $2.6350 as the company entered into definitive agreement to sell its Hospitality Solutions business unit to TPG for $1.1 billion.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) rose 17.4% to $8.23.</li>
<li>TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) gained 15.9% to $3.5350.</li>
<li>Rapport Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) climbed 12.6% to $11.96.</li>
<li>VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) gained 12.2% to $47.83.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) rose 12% to $24.49 as the company announced the FDA approval of its yield enhancement production process.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) gained 10% to $25.79.</li>
<li>UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) gained 10% to $10.85 after the company highlighted nearly four-year duration of response in OLYMPUS long-term follow-up study of JELMYTO.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) rose 7.6% to $7.41.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) gained 6.1% to $29.82.</li>
<li>Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) rose 5.4% to $6.63. Truist Securities analyst Youssef Squali upgraded Peloton Interactive from Hold to Buy.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45038052/top-2-industrials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

CGON

Hims & Hers Health, Inc. Class A Common Stock

HIMS

PLUG

PONY

PTON

RAPP

SABR

SMMT

URGN

VEON

WOLF

Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday

ADMA Biologics Announces FDA Approval Of Its Yield Enhancement Production Process

ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA's strategic advantage through fully U.S.-based manufacturing operations, commercialization and end-market sales, and a vertically integrated U.S.-based supply chain.
"ADMA is a U.S.-based company with all manufacturing operations, end-market sales, and customer engagements conducted exclusively within the United States," said Adam Grossman, President and Chief Executive Officer of ADMA. "The tariffs that have been implemented on foreign goods, services and manufacturing should have no impact on ADMA and its supply chain or production operations. The Company's vertically integrated supply chain is fully domiciled in the U.S., providing end-to-end domestic control over sourcing, manufacturing, and distribution. Our strategic infrastructure not only ensures enhanced supply chain robustness, resilience and regulatory compliance, but also aligns with increasing federal and private sector preferences for U.S.-made products and services. By maintaining complete operational control within the U.S., ADMA is uniquely well-positioned to capitalize on national economic incentives and deliver reliable, secure, and high-quality offerings to its domestic customer base."

Government

Regulations

ADMA Highlights US-Based Supply Chain as Key Advantage in Tariff Era

ADMA Biologics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NYSE">ADMA</a>) short percent of float has risen 5.32% since its last report. The company recently reported that it has 15.07 million shares sold short, which is 6.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>ADMA Biologics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743601526_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ADMA Biologics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ADMA Biologics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, ADMA Biologics's peer group average for short interest as a percentage of float is 11.56%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around ADMA Biologics?

Options

ADMA Biologics Option Alert: May 16 $19 Calls Sweep (5) Near The Ask: 1200 @ $2.3 vs 2667 OI; Earnings 5/8 After Close [est] Ref=$19.7

ADMA Biologics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NYSE">ADMA</a>) short percent of float has risen 4.18% since its last report. The company recently reported that it has 13.74 million shares sold short, which is 5.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>ADMA Biologics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741707918_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ADMA Biologics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ADMA Biologics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, ADMA Biologics's peer group average for short interest as a percentage of float is 13.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ADMA Biologics shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results.

Cantor Fitzgerald analyst Kristen Kluska reiterates ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Overweight and maintains $25 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $25 Price Target

ADMA Biologics shares are trading higher following better-than-expected Q4 revenue results.

ADMA Biologics Q4 2024 Adj. EPS $0.14 Misses $0.15 Estimate

Press Releases

ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update

ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls

ADMA Biologics Statement on Tariffs

General

ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth

ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

Comments

ADMA Biologics

Vendite allo scoperto

ADMA Biologics (NASDAQ:ADMA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO